MXPA03005218A - Peptidos y/o proteinas y uso de los mismos para la produccion de un medicamento terapeutico y/o profilactico. - Google Patents

Peptidos y/o proteinas y uso de los mismos para la produccion de un medicamento terapeutico y/o profilactico.

Info

Publication number
MXPA03005218A
MXPA03005218A MXPA03005218A MXPA03005218A MXPA03005218A MX PA03005218 A MXPA03005218 A MX PA03005218A MX PA03005218 A MXPA03005218 A MX PA03005218A MX PA03005218 A MXPA03005218 A MX PA03005218A MX PA03005218 A MXPA03005218 A MX PA03005218A
Authority
MX
Mexico
Prior art keywords
group
peptides
proteins
therapeutic
production
Prior art date
Application number
MXPA03005218A
Other languages
English (en)
Inventor
Petzelbauer Peter
Original Assignee
Fibrex Medical Res & Dev Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrex Medical Res & Dev Gmbh filed Critical Fibrex Medical Res & Dev Gmbh
Publication of MXPA03005218A publication Critical patent/MXPA03005218A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La invencion se refiere a peptidos o proteinas de la formula general (1) (ver formula) en donde R1 y R2 independientemente = hidrogeno, un grupo hidrocarburo saturado o no saturado con 1 a 3, en particular hasta 10 atomos de carbono, Z1 = un grupo histidina o prolina, Z2 = un grupo arginina, un grupo de peptido o grupo de proteina con arginina en el termino inicial, en particular con 2 a 30 aminoacidos y las sales de los mismos asi como por ejemplo las amidas d e los mismos, o mezclas de materiales d e los mismos y/o con por lo menos un material adicional; la formula (1) se puede utilizar para aplicaciones terapeuticas y/o profilacticas en medicina humana y/o veterinaria.
MXPA03005218A 2000-12-12 2001-12-07 Peptidos y/o proteinas y uso de los mismos para la produccion de un medicamento terapeutico y/o profilactico. MXPA03005218A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT20632000 2000-12-12
PCT/AT2001/000387 WO2002048180A2 (de) 2000-12-12 2001-12-07 Peptide und/oder proteine sowie verwendung desselben zur herstellung eines therapeutischen und/oder präventiven arzneimittels

Publications (1)

Publication Number Publication Date
MXPA03005218A true MXPA03005218A (es) 2004-12-03

Family

ID=3689750

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03005218A MXPA03005218A (es) 2000-12-12 2001-12-07 Peptidos y/o proteinas y uso de los mismos para la produccion de un medicamento terapeutico y/o profilactico.

Country Status (31)

Country Link
US (4) US7271144B2 (es)
EP (2) EP1341819B1 (es)
JP (1) JP4181874B2 (es)
KR (1) KR100864069B1 (es)
CN (2) CN101676299A (es)
AT (2) ATE425184T1 (es)
AU (1) AU2002221316A1 (es)
BG (1) BG107891A (es)
BR (1) BR0116122A (es)
CA (1) CA2430972C (es)
CY (2) CY1106108T1 (es)
CZ (1) CZ20031630A3 (es)
DE (2) DE50110182D1 (es)
DK (2) DK1341819T3 (es)
EA (1) EA005576B1 (es)
EE (1) EE200300283A (es)
ES (2) ES2323963T3 (es)
HK (1) HK1084400A1 (es)
HR (1) HRP20030564A2 (es)
HU (1) HUP0401536A3 (es)
IL (2) IL156360A0 (es)
MX (1) MXPA03005218A (es)
NO (1) NO330767B1 (es)
NZ (1) NZ550619A (es)
PL (2) PL209419B1 (es)
PT (2) PT1586586E (es)
SI (2) SI1341819T1 (es)
SK (1) SK7062003A3 (es)
WO (1) WO2002048180A2 (es)
YU (1) YU53803A (es)
ZA (1) ZA200304545B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL209419B1 (pl) 2000-12-12 2011-08-31 Fibrex Medical Res & Dev Gmbh Zastosowanie peptydów lub białek do wytwarzania leku do terapeutycznego i/lub profilaktycznego stosowania w przypadku zapaleń w medycynie i/lub weterynarii
JP2008503503A (ja) * 2004-06-25 2008-02-07 ファイブレックス メディカル リサーチ アンド デベロップメント ゲーエムベーハー ヒトフィブリノゲンのＡα鎖またはＢβ鎖由来のペプチドの、ショックの治療のための利用
FR2879604B1 (fr) * 2004-12-22 2010-08-13 Biomerieux Sa Peptides citrullines derives de la fibrine reconnus par des auto-anticorps specifiques de la polyarthrite rhumatoide, et leurs utilisations
AT502987A1 (de) 2005-12-23 2007-07-15 Fibrex Medical Res & Dev Gmbh Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen
DE602007002553D1 (de) * 2006-02-23 2009-11-05 Fibrex Medical Res & Dev Gmbh Ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung
ZA200807028B (en) * 2006-02-23 2009-11-25 Fibrex Medical Res & Dev Gmbh Peptides and peptide derivatives as well as pharmaceutical compositions containing the same
WO2007095659A1 (de) * 2006-02-23 2007-08-30 Fibrex Medical Research & Development Gmbh Peptide und peptid-derivate, herstellun derselben sowie deren verwendung zur herstellung eines therapeutisch und/oder präventiv wirkenden arzneimittels
FR2900657B1 (fr) * 2006-05-03 2009-04-17 Univ Toulouse Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide
US8722623B2 (en) 2007-09-17 2014-05-13 University Of Maryland, Baltimore Compositions and methods utilizing fibrin beta chain fragments
FR2908134B1 (fr) * 2007-12-04 2012-10-12 Univ Toulouse 3 Paul Sabatier Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide
JP5410997B2 (ja) * 2008-01-31 2014-02-05 則行 川村 うつ病およびうつ状態のマーカーおよびそれを用いた検出・診断
US20090286725A1 (en) * 2008-05-15 2009-11-19 Fibrex Medical Research & Development Gmbh Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
US8088890B2 (en) * 2008-09-26 2012-01-03 Fibrex Medical Research & Development Gmbh Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
WO2010043444A2 (en) * 2008-10-15 2010-04-22 Fibrex Medical Research & Development Gmbh Pharmaceutical preparation for the treatment and/or prevention of ischemia/reperfusion injury and the sequels thereof
US20100152832A1 (en) * 2008-12-12 2010-06-17 Medtronic Vascular, Inc. Apparatus and Methods for Treatment of Aneurysms With Fibrin Derived Peptide B-Beta
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927916A (en) 1984-04-23 1990-05-22 The General Hospital Corporation Method of producing fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity using fibrin-specific peptides
US5965107A (en) * 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
DE19729591A1 (de) * 1997-07-10 1999-02-11 Therasorb Medizinische Systeme Mittel zur Behandlung und/oder Prophylaxe von Mikrozirkulationsstörungen
FR2795735B1 (fr) * 1999-07-01 2001-09-07 Univ Toulouse Derives citrullines de la fibrine et leur utilisation pour le diagnostic ou le traitement de la polyarthrite rhumatoide
PL209419B1 (pl) 2000-12-12 2011-08-31 Fibrex Medical Res & Dev Gmbh Zastosowanie peptydów lub białek do wytwarzania leku do terapeutycznego i/lub profilaktycznego stosowania w przypadku zapaleń w medycynie i/lub weterynarii
US7201763B2 (en) * 2001-10-24 2007-04-10 Boston Scientific Scimed, Inc. Distal balloon waist material relief and method of manufacture

Also Published As

Publication number Publication date
PT1341819E (pt) 2006-10-31
EP1586586A2 (de) 2005-10-19
CY1109107T1 (el) 2014-07-02
ES2323963T3 (es) 2009-07-28
IL156360A (en) 2012-12-31
PT1586586E (pt) 2010-05-28
KR100864069B1 (ko) 2008-10-16
SI1341819T1 (sl) 2006-10-31
US20040192596A1 (en) 2004-09-30
US20090088384A1 (en) 2009-04-02
SK7062003A3 (en) 2003-11-04
US20070037749A1 (en) 2007-02-15
CA2430972C (en) 2014-08-05
EP1341819B1 (de) 2006-06-14
CN1518558A (zh) 2004-08-04
NO20032656L (no) 2003-06-12
BR0116122A (pt) 2003-10-14
KR20030060988A (ko) 2003-07-16
DE50110182D1 (de) 2006-07-27
AU2002221316A1 (en) 2002-06-24
EA005576B1 (ru) 2005-04-28
SI1586586T1 (sl) 2009-08-31
CN101676299A (zh) 2010-03-24
DK1341819T3 (da) 2006-10-16
ATE425184T1 (de) 2009-03-15
PL362924A1 (en) 2004-11-02
US7811985B2 (en) 2010-10-12
PL209419B1 (pl) 2011-08-31
NO20032656D0 (no) 2003-06-12
HRP20030564A2 (en) 2005-06-30
EP1341819A2 (de) 2003-09-10
EP1586586A3 (de) 2006-03-29
HUP0401536A3 (en) 2008-09-29
US7271144B2 (en) 2007-09-18
CA2430972A1 (en) 2002-06-20
US7494973B2 (en) 2009-02-24
IL156360A0 (en) 2004-01-04
BG107891A (bg) 2004-08-31
EA200300678A1 (ru) 2003-10-30
CN1518558B (zh) 2010-06-16
CY1106108T1 (el) 2011-06-08
DE50114771D1 (de) 2009-04-23
JP4181874B2 (ja) 2008-11-19
PL209752B1 (pl) 2011-10-31
HUP0401536A2 (hu) 2004-11-29
WO2002048180A3 (de) 2003-01-30
EP1586586B1 (de) 2009-03-11
ES2266093T3 (es) 2007-03-01
NZ550619A (en) 2008-06-30
JP2004527469A (ja) 2004-09-09
US20090137464A1 (en) 2009-05-28
ZA200304545B (en) 2004-09-13
YU53803A (sh) 2006-03-03
WO2002048180A2 (de) 2002-06-20
US8067373B2 (en) 2011-11-29
HK1084400A1 (en) 2006-07-28
EE200300283A (et) 2003-10-15
DK1586586T3 (da) 2009-06-29
NO330767B1 (no) 2011-07-11
ATE329614T1 (de) 2006-07-15
CZ20031630A3 (cs) 2003-10-15

Similar Documents

Publication Publication Date Title
MXPA03005218A (es) Peptidos y/o proteinas y uso de los mismos para la produccion de un medicamento terapeutico y/o profilactico.
CA1223198A (en) Repair of tissue in animals
CA2370289A1 (en) Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
TW343198B (en) Cyclopeptides useful as adhesion inhibitors, process for the preparation thereof, and pharmaceutical composition containing them
ATE183514T1 (de) Peptide des menschlichen proteins p53 zum gebrauch in menschlichen-zytotoxischen-t-zell- antwort-induzierenden kompositionen sowie menschliche p53-protein-spezifische t-lymphocyten
MX361694B (es) Fragmentos de peptidos para inducir sintesis de proteinas de matriz extra-celular.
EA200000652A1 (ru) Кристаллы глюкагоноподобного пептида 1
WO2000012542A3 (en) Cytotoxic lactoferrin derivatives modified by bulky or lipophilic moieties
KR880009045A (ko) 혈액 응고 방지성 펩티드
HU902697D0 (en) Process for the enzymatic removal of the n-terminal sequence of proteins
IL175319A0 (en) Novel phosphate-binding protein, pharmaceutical compositions containing same and use thereof
DE69731097D1 (de) Conotoxin peptid pviia
CY1109631T1 (el) Χρησιμοποιηση πεπτιδιων, τα οποια εχουν παραχθει απο την αα- ή ββ-αλυσιδα του ανθρωπινου ινωδογονου, για τη θεραπεια σοκ
MX9703642A (es) Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana.
DE69827262D1 (de) Penaeidine: antimikrobielle peptide aus krebstieren
NZ591827A (en) Biologically active peptides comprising PTTKTYFPHF and their uses in the manufacture of a medicament for modulating immune reaction in a radiotherapy-induced immuno-compromised subject
KR910009730A (ko) 펩티드
PT918795E (pt) Droga antiangiogenica para tratar cancro artrite e retinopatia
ATE223927T1 (de) Mu-opioidligande: agonisten und antagonisten
AU2676399A (en) Novel cystine knot protein and materials and methods for making it
HUP0203504A2 (hu) Immunterápiás alkalmazásra szolgáló módosított peptidek és peptid-mimetikumok
KR890014735A (ko) 변형 단백질
KR20140084191A (ko) 멜라노트란스페린으로부터 유도된 펩티드 화합물 및 이의 용도
Murakami et al. A cytocidal tissue kallikrein isolated from mouse submandibular glands
GB9604518D0 (en) Novel compounds

Legal Events

Date Code Title Description
FG Grant or registration